These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12142388)

  • 61. Serum levels of tissue inhibitor of metalloproteinases in patients with mixed connective tissue disease.
    Jinnin M; Ihn H; Yamane K; Asano Y; Yazawa N; Tamaki K
    Clin Exp Rheumatol; 2002; 20(4):539-42. PubMed ID: 12175110
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
    Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
    Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.
    Jordán A; Roldán V; García M; Monmeneu J; de Burgos FG; Lip GY; Marín F
    J Intern Med; 2007 Sep; 262(3):385-92. PubMed ID: 17697160
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Ventricular remodeling and matrix metalloproteinase-1 and its tissue inhibitor of metalloproteinase-1 in serum in third trimester of pregnant women with cardiac disease.].
    Zhang ZL; Lin JH; Tao RQ
    Zhonghua Fu Chan Ke Za Zhi; 2009 Oct; 44(10):731-5. PubMed ID: 20078957
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systemic dilation diathesis in patients with abdominal aortic aneurysms: a role for matrix metalloproteinase-9?
    van Laake LW; Vainas T; Dammers R; Kitslaar PJ; Hoeks AP; Schurink GW
    Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):371-7. PubMed ID: 15749037
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diagnostic significance of TIMP-1 level in serum and its immunohistochemical expression in colorectal cancer patients.
    Niewiarowska K; Pryczynicz A; Dymicka-Piekarska V; Gryko M; Cepowicz D; Famulski W; Kemona A; Guzińska-Ustymowicz K
    Pol J Pathol; 2014 Dec; 65(4):296-304. PubMed ID: 25693084
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer.
    Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
    Cancer Lett; 2000 Apr; 151(1):81-6. PubMed ID: 10766426
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
    Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening SA
    Int J Cancer; 2000 Mar; 85(6):801-4. PubMed ID: 10709099
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
    Komosinska-Vassev K; Olczyk P; Winsz-Szczotka K; Kuznik-Trocha K; Klimek K; Olczyk K
    Gerontology; 2011; 57(1):44-52. PubMed ID: 20215736
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma.
    Kuvaja P; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Int J Cancer; 2008 Aug; 123(4):846-51. PubMed ID: 18506691
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A study of metalloproteinases in fifty joint fluid specimens.
    Gaudin P; Razakaboay M; Surla A; Berthier S; Fauconnier J; Morel F; Phelip X
    Rev Rhum Engl Ed; 1997 Jun; 64(6):375-81. PubMed ID: 9513609
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
    Frederiksen C; Lykke J; Christensen IJ; Brünner N; Nielsen HJ
    Scand J Clin Lab Invest; 2007; 67(5):545-52. PubMed ID: 17763191
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1.
    Møller Sørensen N; Dowell BL; Stewart KD; Jensen V; Larsen L; Lademann U; Murphy G; Nielsen HJ; Brünner N; Davis GJ
    Tumour Biol; 2005; 26(2):71-80. PubMed ID: 15870512
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.
    Niemirska A; Litwin M; Trojanek J; Gackowska L; Kubiszewska I; Wierzbicka A; Kułaga Z; Michałkiewicz J
    J Hypertens; 2016 Sep; 34(9):1815-22. PubMed ID: 27379542
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.